Sai-Hong Ignatius Ou, MD, PhD
Chao Family Comprehensive Cancer Center, University of California Irvine Healthcare, 101 City Drive, Bldg 56, RT 81, Rm241, Orange, CA 92868-3298, USA
Dr. Sai-Hong Ignatius Ou completed his MD PhD at the University of Texas Southwestern Medical Center in Dallas, Texas; his medicine residency at Duke University Medical Center, Durham, North Carolina; and his hematology-oncology fellowship training at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, Massachusetts. Dr. Ou is board-certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine. Dr. Ou joined the University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center (an NCI-designated Comprehensive Cancer Center) immediately after completing his fellowship as an assistant clinical professor in 2003 and has been promoted to Clinical Professor in 2015. He has published 90 peer-reviewed manuscripts (including New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Cancer Discovery, Nature Medicine) primarily in the field in targeted therapy in lung cancer and the prognostic and predictive significance of smoking status and ethnicity in the outcome of lung cancer. In particular, Dr. Ou is one of the seven original principal investigators for the still ongoing phase I crizotinib trial that has led to the approval of crizotinib for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). Recently, the activity of crizotinib in ROS1-rearranged NSCLC has been reported in New England Journal of Medicine in which Dr. Ou is co-first author. Currently Dr. Ou is involved in many early phase clinical trials involving novel and second-generation tyrosine kinase inhibitors in NSCLC driven by receptor tyrosine kinase rearrangement or mutations. Dr. Ou is also involved in the clinical trial of anti-PD-L1, MEDI4736 in numerous tumor types including squamous and non-squamous NSCLC. Dr. Ou is on the editorial board for Critical Review in Hematology/Oncology, Clinical Lung Cancer and ad hoc reviewers for many journals including for New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Oncology. Dr. Ou is a member of the scientific program committee for metastatic non-small lung cancer track for the American Society of Clinical Oncology (ASCO) from 2016 to 2018. Finally, Dr. Ou has been voted as one of America’s Best Doctors five years in a row since 2009.